


REMARKS

By the present Amendment, the claims are amended to omit their multiple dependency. A Version with Markings Showing Changes Made is attached. Claims 15-21 are added. Support for claims 15-17 may be found in original claim 13, support for claim 18 may be found in original claim 6 and support for claims 19-21 may be found in original claim 14. It is believed that these changes do not involve any introduction of new matter, whereby entry is believed to be in order.

Respectfully submitted,



Holly D. Kozlowski
Registration No. 30,468
Dinsmore & Shohl LLP
1900 Chemed Center
255 East Fifth Street
Cincinnati, Ohio 45202
(513) 977-8568

692503.01

VERSION WITH MARKINGS SHOWING CHANGES MADE

6. (Amended) A cultured host cell harboring a vector according to claim 4 [or 5]. An injector device for delivery of liquid from a high pressure source, the device comprising

10. (Amended) A method for identifying an agent useful for stimulating the biological activities of a mammalian IPAS polypeptide, said method comprising the steps

(i) contacting a candidate agent with the mammalian IPAS polypeptide according to claim 2 [or 3]; and

(ii) determining whether said candidate agent stimulates the biological activities of the said polypeptide.

11. (Amended) A method for identifying an agent useful for the inhibition of angiogenesis and/or tumor growth, said method comprising the steps

(i) contacting a candidate agent with a mammalian IPAS polypeptide according to claim 2 [or 3]; and

(ii) determining whether said candidate agent stimulates the biological activities of the said polypeptide, such stimulation being indicative for an agent useful for the treatment of a medical condition related to angiogenesis and/or tumor growth.

13. (Amended) A method for the treatment of angiogenic disease or tumor growth, comprising administering to a subject an effective amount of an agent identified by the method according to claim 8 [any one of claims 8 to 11].

14. (Amended) The [use or] method according to claim [12 or] 13, wherein said angiogenic disease is related to ischemic cardiovascular lesions, stroke, or diabetic microvascular diseases.

09895791.062901